Xeris Pharmaceuticals’ new glucagon injection (Gvoke HypoPen), a ready-to-use glucagon formulation in a premixed autoinjector, is now available by prescription.
Xeris Pharmaceuticals’ glucagon injection (Gvoke HypoPen) is now available by prescription in the United States for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and older, according to a press release.
The glucagon injection is a ready-to-use glucagon in a premixed autoinjector, with no visible needle, according to Xeris. The easy-to-use pen is available in 2 doses: 0.5 mg/0.1 mL for children who weigh less than 100 pounds and 1 mg/0.2 mL for adolescents and adults who weigh 100 pounders or greater.
According to Xeris, the glucagon injection’s simple administration guarantees a reliable method of delivery, with 99% of patients who were able to use it correctly in studies. Additionally, studies also showed that 99% of adults and 100% of children had their blood sugars raised to safe levels with use.
“Gvoke HypoPen allows the diabetes community to change how we approach treating severe low blood sugar events,” Bruce Bode, MD, FACE, Atlanta Diabetes Associates, said in a statement. “Anyone can use Gvoke HypoPen in 2 simple steps. That opens the door for some patients to even give it to themselves, in certain situations. My hope is that what was once considered a crisis moment, can now become a manageable situation with Gvoke HypoPen.”
For limited time, eligible commercially insured patients may pay as little as $0 for a 2-pack of Gvoke HypoPen by using the Gvoke copay savings card. Xeris also offers a Patient Assistance Program to help those who qualify, according to the release.
Xeris Pharmaceuticals Announces Gvoke HypoPen – the First Autoinjector for Severe Hypoglycemia – Now Available. News Release. Xeris Pharmaceuticals; July 1, 2020. Accessed July 6, 2020. https://investors.xerispharma.com/node/7721/pdf